Monday, April 15, 2024
HomePoliticsDirect Biologics reveals successful outcomes from EXIT COVID-19 Phase II Clinical Trial

Direct Biologics reveals successful outcomes from EXIT COVID-19 Phase II Clinical Trial

Austin [Texas], April 6 (ANI/PRNewswire): Direct Biologics, a regenerative biotechnology company with a lifesaving mesenchymal stem cell (MSC) derived extracellular vesicle (EV) platform technology, announces topline results from its first-in-human, multicenter, Phase II double-blind, placebo-controlled, randomized clinical trial, EXIT COVID-19, today which used the EV product ExoFlo to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS).

“Overall, ExoFlo demonstrated a robust safety and efficacy profile that warrants further clinical investigation with a pivotal Phase III study. In addition to an unequaled reduction in 60-day mortality rate of 37.6% in comparison to placebo, no reportable adverse events were observed,” said Dr Vikram Sengupta, Chief Medical Officer. “ExoFlo also substantially outperformed placebo with respect to time to discharge and ventilator free days. Additionally, subgroup analysis revealed a larger mortality benefit among patients who were severely hypoxic at randomization,” he said.

“With the recent emergence of the BA.2 variant, healthcare providers across the US are preparing for another wave of hospitalizations caused by COVID-19 related ARDS. Under the present standard of care, the mortality rate still exceeds thousands of lives per week and ARDS due to COVID-19 remains a leading cause of death in the US. There is still a profound unmet need for a novel therapeutic to address this problem, and we believe that ExoFlo is the solution,” said Dr Sascha Sengupta, Associate Chief Medical Officer.

ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation.

Physicians can learn more and may request information on becoming a study site at http://www.clinicaltrials.gov. For more information on Direct Biologics and regenerative medicine, visit: https://directbiologics.com.

Direct Biologics, LLC, is headquartered in Austin, Texas, with an R&D facility located at the University of California, and an Operations and Order Fulfillment Center located in San Antonio, Texas. Direct Biologics is a market-leading innovator and cGMP manufacturer of regenerative medical products, including a robust extracellular vesicle based biologic platform technology. Direct Biologics’ management team holds extensive collective experience in biologics research, development, and commercialization, making it the leader in the evolving space of next generation biologics. Direct Biologics is dedicated to pursuing additional clinical applications of ExoFlo through the FDA’s investigational new drug application process. For more information visit https://directbiologics.com.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content.


Source: The Print

RELATED ARTICLES
- Advertisment -

Most Popular

Recent Comments